Merck & Company Inc (MRK)
KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Significantly Improved Event-Free Survival, Overall Survival and Pathologic Complete Response Rates for Cisplatin-Eligible Patients with MIBC When Given Before and After Surgery
📈 **POSITIVE** • High confidence analysis (80%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (95%) **Content type:** Business